The molecular dissection of the landscape of AML has been at the leading edge of cancer discovery, but the treatment of AML has remained largely unchanged. A defining feature of AML is a differentiation defect, yet current therapy focuses almost exclusively on cytotoxic chemotherapy. In this issue, Järås et al. report that Csnk1a1 inhibition induces differentiation in AML and is selectively essential for AML survival in vivo. Because Csnk1a1 is a druggable target, this work identifies a propitious new strategy for the treatment of AML and also demonstrates the value of re-mining existing data sets.
